LUGPA Policy Brief - American Cancer Society Updates Prostate Cancer Screening Guidelines

November 2026

At a Glance

  • What: The American Cancer Society (ACS) updated its prostate cancer screening guidelines for the first time since 2010, moving toward routine PSA-based screening for average-risk men.
  • Average-Risk Men: PSA screening every two years for men ages 50–69.
  • Higher-Risk Men: Annual screening beginning at age 45 for Black men and men with a strong family history of prostate cancer.
  • Additional Recommendations: Updated guidance addresses elevated PSA results, MRI and biomarker testing, biopsy decisions, and active surveillance.
  • Why It Matters: The recommendations reinforce the role of early detection and could increase screening and referrals to urology practices.

What Happened

On November 12, 2026, the American Cancer Society (ACS) released updated prostate cancer screening guidelines, representing its first major revision since 2010. The new recommendations reflect additional evidence supporting the benefits of PSA-based screening, along with advances in diagnostic tools and approaches to managing prostate cancer that can help reduce unnecessary biopsies and treatment.

The most significant change is a direct recommendation for routine PSA screening among average-risk men ages 50–69, rather than relying primarily on individualized discussions between patients and physicians about whether to undergo testing.

The updated recommendations include:

  • Average-Risk Men (Ages 50–69): PSA-based screening every two years.
  • Black Men (Ages 45–69): Annual PSA-based screening, recognizing their increased risk of developing and dying from prostate cancer.
  • Men with a Strong Family History (Ages 45–69): Annual screening for non-Black men with a first-degree relative diagnosed before age 65 or multiple first-degree relatives diagnosed with prostate cancer.
  • Men with One First-Degree Relative Diagnosed at Age 65 or Older: Screening every two years beginning at age 45.
  • Men Ages 70–74: Individualized decisions about continuing screening, taking into account overall health, life expectancy, and the potential benefits and harms.
  • Men Ages 75 and Older: Screening is generally not recommended. The guidelines also advise against screening men with a life expectancy of less than 10 years.

The updated guidance also provides recommendations for follow-up after an elevated PSA result. Men ages 45–69 with PSA levels of 3.0 ng/mL or higher should have repeat testing within two weeks to three months. For confirmed elevations, clinicians should offer MRI and/or validated biomarker testing to help guide decisions about whether a biopsy is appropriate.

For men diagnosed with low-risk prostate cancer, the ACS recommends active surveillance as the initial management approach to avoid unnecessary treatment while maintaining appropriate monitoring.

Why It Matters

Prostate cancer remains one of the most commonly diagnosed cancers among men and the second-leading cause of cancer death among men in the United States. The ACS estimates that approximately 333,830 men will be diagnosed with prostate cancer and 36,320 will die from the disease in 2026.

The updated recommendations reflect growing evidence that PSA-based screening can reduce prostate cancer mortality and the likelihood of diagnosis at an advanced stage. They also recognize improvements in diagnostic approaches that can help distinguish potentially aggressive cancers from those that may not require immediate treatment.

The shift toward routine screening could have several implications:

  • Earlier Detection: More consistent PSA screening may help identify prostate cancer before it advances, potentially improving treatment options and outcomes.
  • Increased Screening and Referrals: A direct recommendation for average-risk men could encourage more primary care providers to incorporate PSA testing into routine preventive care and increase referrals to urologists.
  • Addressing Disparities: Earlier and more frequent screening recommendations for Black men recognize their disproportionate burden of prostate cancer and the importance of improving early detection.
  • Reducing Unnecessary Treatment: Greater emphasis on repeat PSA testing, MRI, biomarkers, and active surveillance may help reduce unnecessary biopsies and treatment-related complications.
  • Greater Awareness: The updated guidelines provide an opportunity to strengthen patient education and communication between primary care providers and urologists regarding screening and follow-up.

Implications for LUGPA Members

The revised ACS guidelines provide an opportunity for independent urology practices to reinforce their role in prostate cancer screening, early detection, and comprehensive patient care.

Primary Care Engagement: Practices can work with primary care providers to communicate the updated recommendations, encourage appropriate PSA testing, and establish referral pathways for patients with elevated PSA results or increased risk.

Patient Education: The stronger recommendation for routine screening may increase patient interest in PSA testing. Urology practices can help patients understand screening intervals, individual risk factors, and the benefits and limitations of testing.

Diagnostic and Follow-Up Services: The recommendations emphasize the importance of evaluating elevated PSA results through repeat testing, MRI, and biomarker testing when appropriate. Practices should be prepared to address potential increases in demand for these services and associated follow-up care.

Access to Advanced Care: The updated guidance reinforces the importance of access to comprehensive urologic services, including diagnostic evaluation, biopsy when indicated, treatment, and active surveillance for patients with low-risk disease.

LUGPA Perspective

LUGPA views the updated ACS recommendations as an important development in prostate cancer early detection. The shift toward routine PSA screening for average-risk men, combined with earlier screening for higher-risk populations, reinforces the importance of identifying prostate cancer at a stage when treatment options may be more effective.

The recommendations also highlight the need to balance early detection with appropriate diagnostic evaluation and avoidance of unnecessary treatment. Independent urology practices play an important role throughout this process, from screening and risk assessment to advanced diagnostics, treatment, and ongoing surveillance.

LUGPA will continue to monitor developments in prostate cancer screening recommendations and their implications for patient access, early detection, and independent urology practices.

Additional Resources